4//SEC Filing
Decheng Capital China Life Sciences USD Fund III, L.P. 4
Accession 0001209191-22-051370
CIK 0001626199other
Filed
Sep 26, 8:00 PM ET
Accepted
Sep 27, 4:46 PM ET
Size
9.7 KB
Accession
0001209191-22-051370
Insider Transaction Report
Form 4
Transactions
- Award
Common Stock
2022-09-23$7.35/sh+639,456$4,700,002→ 5,347,744 total - Award
Common Stock
2022-09-23$7.35/sh+1,360,544$9,999,998→ 1,360,544 total(indirect: See footnote)
Footnotes (2)
- [F1]The reportable securities are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. ("Fund III"). Decheng Capital Management III (Cayman), LLC ("GP III") is the general partner of Fund III. Xiangmin Cui is the manager of GP III. Each of Fund III, GP III and Dr. Cui may be deemed to beneficially own the securities held by Fund III. GP III disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
- [F2]The reportable securities are held directly by Decheng Capital Global Healthcare Fund (Master), LP ("Healtchcare"). Decheng Capital Global Healthcare GP, LLC ("Healthcare GP") is the general partner of Healthcare. Xiangmin Cui is the indirect managing member and ultimate beneficial owner of Healthcare GP. Each of Healthcare, Healthcare GP and Dr. Cui may be deemed to beneficially own the securities held by Healthcare. Healthcare GP disclaims beneficial ownership of these securities, except to the extent of its pecuniary interest therein. Dr. Cui is a director of the Issuer and files separate Section 16 reports.
Documents
Issuer
ALPINE IMMUNE SCIENCES, INC.
CIK 0001626199
Entity typeother
IncorporatedCayman Islands
Related Parties
1- filerCIK 0001736814
Filing Metadata
- Form type
- 4
- Filed
- Sep 26, 8:00 PM ET
- Accepted
- Sep 27, 4:46 PM ET
- Size
- 9.7 KB